Calix Ltd (ASX: CXL) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Calix Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $1.04 billion
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 161.20 million
Earnings per share -0.061
Dividend per share N/A
Year To Date Return 500.93%
Earnings Yield N/A
Franking 60%
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

Calix Ltd (ASX: CXL)
Latest News

Dividend Payment History Data provided by Morningstar.

Data provided by Morningstar.
Ex-Date Amount Franking Type Payable
30 Jun 2004 $0.0500 60.00% 09 Jul 2004

CXL ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About Calix Ltd

Calix Ltd Australian technology company. It has developed a patent-protected, platform technology that produces new materials and processes, targeted at solving global challenges in water and wastewater treatment, sustainable food production, CO2 mitigation, and advanced battery development. Its core technology platform includes the Calix Flash Calciner (CFC). It has operations in Australia, New Zealand, Asia, Europe, and the United States of America.

CXL Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
03 Dec 2021 $6.45 $-0.01 -0.15% 162,209 $6.51 $6.65 $6.35
02 Dec 2021 $6.46 $-0.21 -3.15% 465,116 $6.53 $6.60 $6.40
01 Dec 2021 $6.67 $-0.21 -3.05% 675,424 $6.75 $6.93 $6.60
30 Nov 2021 $6.88 $0.65 10.43% 1,101,242 $6.26 $6.98 $6.26
29 Nov 2021 $6.23 $-0.37 -5.61% 1,158,076 $6.33 $6.60 $6.20
26 Nov 2021 $6.60 $-0.43 -6.12% 680,124 $7.00 $7.17 $6.55
25 Nov 2021 $7.03 $-0.25 -3.43% 172,186 $7.28 $7.28 $7.03
24 Nov 2021 $7.28 $0.00 0.00% 248,683 $7.33 $7.44 $7.17
23 Nov 2021 $7.28 $-0.01 -0.14% 352,635 $7.30 $7.35 $7.01
22 Nov 2021 $7.29 $-0.59 -7.49% 731,260 $7.84 $7.90 $6.95
19 Nov 2021 $7.88 $0.24 3.14% 201,167 $7.75 $7.97 $7.59
18 Nov 2021 $7.64 $-0.35 -4.38% 300,446 $7.98 $8.02 $7.61
17 Nov 2021 $7.99 $0.05 0.63% 871,417 $8.08 $8.30 $7.84
16 Nov 2021 $7.94 $0.80 11.20% 857,766 $7.20 $7.99 $7.05
15 Nov 2021 $7.14 $-0.20 -2.72% 603,085 $7.35 $7.39 $6.90
12 Nov 2021 $7.34 $1.22 19.93% 1,229,051 $6.53 $7.50 $6.46
11 Nov 2021 $6.12 $0.17 2.86% 274,174 $5.95 $6.20 $5.82
10 Nov 2021 $5.95 $-0.25 -4.03% 296,114 $6.23 $6.23 $5.90
09 Nov 2021 $6.20 $0.31 5.26% 359,411 $5.99 $6.22 $5.91
08 Nov 2021 $5.89 $-0.36 -5.76% 370,958 $6.29 $6.29 $5.89
05 Nov 2021 $6.25 $0.06 0.97% 462,541 $6.19 $6.27 $6.06
04 Nov 2021 $6.19 $0.31 5.27% 487,548 $5.92 $6.20 $5.79

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
27 Oct 2021 Mark Sceats Transfer 49 $257,400
Off-market transfer.
11 Oct 2021 Philip (Phil) Hodgson Buy 204 $1,133,437
Conversion of securities.
11 Oct 2021 Philip (Phil) Hodgson Exercise 204 $1,133,437
Conversion of securities. 1,035,160 - Performance Rights
06 Oct 2021 Helen Fisher Buy 2 $9,850
On-market trade.
29 Sep 2021 Helen Fisher Buy 3 $17,539
On-market trade.
13 Apr 2021 Mark Sceats Buy 4 $9,558
Participation in share purchase plan. As per announcement on 16/04/2021.
13 Apr 2021 Peter Turnbull Buy 4 $9,558
Participation in share purchase plan.
13 Apr 2021 John (Jack) Hamilton Buy 11 $23,894
Participation in share purchase plan.
13 Apr 2021 John (Jack) Hamilton Buy 2 $4,778
Participation in share purchase plan.
13 Apr 2021 Philip (Phil) Hodgson Transfer 1 $2,545,927
Off-market transfer. Assuming 1,106,925 Indirect shares transferred to Direct shares.
13 Apr 2021 Philip (Phil) Hodgson Buy 4 $9,558
Participation in share purchase plan.
13 Apr 2021 Philip (Phil) Hodgson Transfer 1 $2,545,927
Off-market transfer. Assuming 1,106,925 Indirect shares transferred to Direct shares.
19 Mar 2021 Helen Fisher Buy 3 $7,941
On-market trade.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr Peter John Turnbull Non-Executive ChairmanNon-Executive Director Feb 2009
Mr Turnbull is an experienced chair and professional non-executive director of publicly listed, unlisted and technology companies in the scale up phase. Sector experience spans technology commercialisation, artificial intelligence, oil and gas, mining and industrial manufacturing. Peter has degrees in law and commerce (University of Melbourne) and over 25 years successful senior executive and corporate legal experience with some of Australia's largest listed and unlisted public companies including Newcrest Mining, BTR Nylex and Energex. He also has corporate regulatory and government policy experience gained through working with the Australian Securities & Investments Commission and the Hong Kong Securities & Futures Commission. He is a member of the ASIC Corporate Governance Consultative Panel and is a regular speaker and writer on global governance issues. In June 2020 he was made a Member of the Order of Australia for services to business and corporate governance institutes. He is a director of Auxita Pty Ltd. He is Chair of the Board and Remuneration & Nomination Committee, member of the Audit & Risk Management Committee
Ms Helen E Fisher Non-Executive Director Sep 2020
Mr Fisher is Managing Director and CEO of Bio Capital Impact Fund (BCIF). Prior to establishing BCIF, Mr Fisher was a partner of Deloitte for over 10 years and led Deloitte's Life Sciences industry practice in Australia for 5 years, having had many years' experience in the Life Sciences and Health Care industry. She also specialised in Financial Services, servicing some of the largest Australian banks and funds in the Funds Management industry and has been involved in setting up a number of large international funds, as well as advised on a number of significant M&A deals. Mr Fisher provided strategic advice to publicly listed and large multinational companies and has experience with capital raisings, licensing deals, demergers, implementing offshore structures, IP management and location, and supply chain management. Mr Fisher is currently a Non-Executive Director and Chair of the Audit and Risk Management Committee of Paradigm Biopharmaceuticals Limited, a company listed on the ASX. She is the Chair of the Victorian branch of AusBiotech.
Mr Lance Adrian Wingate O'Neill Non-Executive Director Feb 2014
Lance O'Neill is a Director of DFB (Australia) Pty Ltd, a Sydney based investment advisory business, and has worked in institutional equity, fixed income sales/trading and corporate finance in international securities and investment markets for over thirty years predominantly in Australia, UK and USA. He is the chair of MediaZest Plc and EP&F Capital Plc and in addition is and has been a director of, and investor in, a number of private and public companies in Australia, UK, and the USA.
Dr Mark Geoffrey Sceats Chief ScientistExecutive Director Feb 2014
Mr Sceats is a qualified physical chemist with 45 years' experience. Mr Sceats has previously worked at the James Franck Institute at the University of Chicago, and as an Assistant Professor of the University of Rochester NY, USA, where he was awarded the Alfred P Sloan Fellowship for his work. Later he was employed by the University of Sydney as a Reader in the School of Chemistry for his research work on chemical reaction kinetics. Mr Sceats has published more than 140 academic papers in physical chemistry and is an inventor of 43 patented inventions. Mr Sceats was awarded the M.A. Sargent Medal of the Institute of Engineers Australia for his contributions to optical communications and the Centenary Medal of the Commonwealth of Australia for his contributions to Australian society. He is a Member of the Technology Committee.
Dr John (Jack) Andrew Hamilton Non-Executive Director Nov 2012
Dr Hamilton has over 30 years' experience both locally and internationally in operations and commercial management covering refining, petrochemicals and gas production, marketing, strategy and liquefied natural gas project management. Mr Hamilton was previously CEO of Exergen Pty Ltd, a low emission coal resource development company and formerly, director of NWS Ventures with Woodside Energy overseeing one of Australia's largest resource projects, the North West Shelf Project. Mr Hamilton is the non-executive chair of AnteoTech Limited (ASX - ADO) and has held numerous publicly-listed non executive director roles including Renu Energy Limited and DUET Group Ltd. He is Chair of Technology Committee and member of the Audit & Risk Management Committee and the Remuneration & Nomination Committee.
Dr Philip (Phil) Hargraves Hodgson Chief Executive OfficerManaging Director Feb 2014
Mr Hodgson has a technical and commercial background from a successful career with Shell, where for over 14 years he developed depth of experience across all key sectors of the downstream oil industry including refining and supply, marketing and sales, pricing strategy, risk management, corporate strategy, and mergers and acquisitions. From 2007 to 2013, Phil ran his own consultancy providing project development, commercial, M&A, and management expertise to several sectors including LNG, biofuel, clean coal, geothermal energy, building products, logistics and fast-moving consumer goods. He is a member of the Technology Committee
Mr Darren Charles Chief Financial OfficerCompany Secretary
-
Darren Charles Chief Financial OfficerCompany Secretary
-
Bill Karis GM Water
-
Hinne Temminck Tuinstra GM Strategy & Portfolio
-
Doug Kelley President of IER
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
J P Morgan Nominees Australia Pty Limited 18,077,761 11.30%
UBS Nominees Pty Ltd 16,815,500 10.51%
HSBC Custody Nominees (Australia) Limited 9,095,412 5.69%
Mr Paul Crowther 8,417,000 5.26%
Nicholas Merriman 8,108,286 5.07%
Citicorp Nominees Pty Limited 6,477,588 4.05%
Dr Mark Geoffrey Sceats 4,402,417 2.75%
Cs Third Nominees Pty Limited <Hsbc Cust Nom Au Ltd 13 A/C> 3,351,058 2.09%
Mark Geoffrey Sceats <Sceats Superannuation Fund> 3,177,015 1.99%
BNP Paribas Noms Pty Ltd <DRP> 2,348,501 1.47%
Cs Fourth Nominees Pty Limited <HSBC Cust Nom Au Ltd 11 A/C> 2,208,560 1.38%
Pigeons Super Pty Limited <The Hodgson Family S/F A/C> 2,193,059 1.37%
National Nominees Limited 2,053,743 1.28%
Brispot Nominees Pty Ltd <House Head Nominee A/C> 2,002,715 1.25%
Mr Jacob Shields Ulrich 1,583,133 0.99%
Brian N C Sweeney 1,490,001 0.93%
Mr Adam Vincent 1,459,724 0.91%
Oliver Gillie & Susan Gillie 1,280,455 0.80%
Jeneil Super Pty Ltd <Jeneil Super Fund A/C> 1,259,311 0.79%
Mr John Andrew Hamilton 1,223,639 0.79%

Profile

since

Note